89bio, Inc.
ETNB
$8.18
-$0.17-2.04%
| Weiss Ratings | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.70 | |||
| Price History | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.54% | |||
| 30-Day Total Return | -6.30% | |||
| 60-Day Total Return | 4.20% | |||
| 90-Day Total Return | 2.38% | |||
| Year to Date Total Return | 2.51% | |||
| 1-Year Total Return | -38.54% | |||
| 2-Year Total Return | -35.18% | |||
| 3-Year Total Return | 137.10% | |||
| 5-Year Total Return | -64.47% | |||
| 52-Week High % Change | -39.10% | |||
| 52-Week Low % Change | 39.50% | |||
| Price | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $13.71 | |||
| 52-Week Low Price | $5.99 | |||
| 52-Week Low Price (Date) | Jan 16, 2025 | |||
| 52-Week High Price (Date) | Mar 18, 2024 | |||
| Valuation | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.22B | |||
| Enterprise Value | 816.56M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.43 | |||
| Earnings Per Share Growth | 70.46% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 2.50 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $8.18 | |||
| Enterprise Value/EBITDA (TTM) | -2.12 | |||
| Enterprise Value/EBIT | -2.12 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 115.96M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 415 432 9270 | |||
| Address | 142 Sansome Street San Francisco, CA 94104 | |||
| Website | www.89bio.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -44.73% | |||
| Return on Equity | -- | |||
| Income Statement | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -384.62M | |||
| EBIT (TTM) | -384.66M | |||
| Net Income (TTM) | -367.08M | |||
| Net Income Avl. to Common (TTM) | -367.08M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -194.16% | |||
| EPS Diluted (TTM) | -3.43 | |||
| EPS Diluted Growth (Q YOY) | -104.71% | |||
| Balance Sheet | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 439.96M | |||
| Cash Per Share (Q) | $3.79 | |||
| Total Current Assets (Q) | 476.45M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 400.79M | |||
| Current Ratio (Q) | 13.187 | |||
| Book Value Per Share (Q) | $3.34 | |||
| Total Assets (Q) | 478.69M | |||
| Total Current Liabilities (Q) | 36.13M | |||
| Total Debt (Q) | 37.55M | |||
| Total Liabilities (Q) | 77.90M | |||
| Total Common Equity (Q) | 400.79M | |||
| Cash Flow | ETNB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -40.86M | |||
| Cash from Financing (TTM) | 218.59M | |||
| Net Change in Cash (TTM) | -190.10M | |||
| Levered Free Cash Flow (TTM) | -237.77M | |||
| Cash from Operations (TTM) | -367.82M | |||
